Aier(SZ:300015)2022-10-25 16:00Financial Performance - The company's operating revenue for Q3 2022 reached ¥4,944,145,432.41, representing a 16.38% increase compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2022 was ¥1,065,786,126.88, marking a 20.06% year-on-year growth[2]. - The net profit after deducting non-recurring gains and losses for the first nine months of 2022 was ¥2,503,571,997.15, an increase of 15.10% year-on-year[2]. - Total operating revenue for the current period reached ¥13,051,536,030.32, an increase of 12.55% compared to ¥11,596,309,877.11 in the previous period[22]. - Net profit for the current period was ¥2,573,101,878.69, representing an 18.49% increase from ¥2,171,719,869.40 in the same period last year[23]. - The total profit for the current period was ¥3,224,213,170.82, compared to ¥2,772,128,831.48 in the previous period, marking a 16.29% increase[23]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥26,893,314,139.82, reflecting a 23.09% increase from the end of the previous year[2]. - The total liabilities of Aier Eye Hospital Group as of September 30, 2022, were RMB 9.73 billion, slightly up from RMB 9.62 billion at the beginning of the year[20]. - The total equity of Aier Eye Hospital Group as of September 30, 2022, was RMB 17.16 billion, up from RMB 12.22 billion at the beginning of the year, representing an increase of approximately 40.5%[21]. Cash Flow - The company's cash flow from operating activities for the first nine months of 2022 was ¥400,230.61 million, up 23.30% year-on-year[8]. - The net cash flow from operating activities for the third quarter was approximately CNY 4.00 billion, an increase of 23.3% compared to CNY 3.25 billion in the same period last year[26]. - The company reported a cash inflow from financing activities of CNY 4.23 billion, compared to CNY 2.06 billion in the previous year, indicating a growth of 105.5%[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 278,141[11]. - The largest shareholder, Aier Medical Investment Group Co., Ltd., holds 34.97% of shares, totaling 2,463,241,139 shares[11]. - Chen Bang, the actual controller, owns 15.77% of shares, amounting to 1,110,570,961 shares[11]. - The company has no known related party relationships among the top ten shareholders, except for Chen Bang and Guo Hongwei, who are related by marriage[12]. Research and Development - Research and development expenses for the first nine months of 2022 were ¥20,232.37 million, an increase of 28.47% compared to the same period last year[8]. - Research and development expenses increased to ¥202,323,748.51, up from ¥157,485,633.86 in the previous period, reflecting a growth of 28.38%[22]. Stock and Shares - The company's basic earnings per share for Q3 2022 was ¥0.0955, a 19.23% increase year-on-year[2]. - Basic and diluted earnings per share were both ¥0.3371, compared to ¥0.2870 in the previous period[24]. - The company issued 133,467,485 shares at a price of RMB 26.49 per share, raising a total of RMB 3.54 billion, with a net amount of RMB 3.51 billion after expenses[16]. Other Financial Metrics - The weighted average return on equity for Q3 2022 was 8.59%, a slight increase of 0.39% compared to the previous year[2]. - The company reported a net cash outflow from asset disposal of ¥1,478,309.36, contrasting with a gain of ¥356,445.37 in the previous period[23]. - The company experienced a foreign exchange loss of -¥68,853,093.75, compared to -¥51,146,453.35 in the previous period, indicating increased volatility[24].